AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Companies with late-stage peptide drugs

47 companies hold rights to 49 peptide drugs (peptide drugs, oral and injected) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.

BiologicsSmall moleculesCell and gene therapiesRNA and oligonucleotide drugsPeptide drugs
Late-stage peptide drugs, by developer
CompanyTickerLate-stageDrugs (stage, indications)
Jiangsu Hengrui Pharmaceuticals6002765HR17031 (Phase 3, Type 2 Diabetes); Insulin sudelidec (INS068) (Phase 3, Type 2 Diabetes); Noiiglutide (Phase 3, Type 2 Diabetes); ribupatide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more); SHR-3167 (Phase 3, Type 2 Diabetes)
Novo NordiskNVO5cagrilintide (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease); cagrilintide/semaglutide (Phase 3, Obesity, Type 2 Diabetes); IcoSema (Phase 3, Type 2 Diabetes); UBT251 (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease); zenagamtide (Phase 3, Obesity, Type 2 Diabetes)
Eli LillyLLY4Brenipatide (Phase 3, Obesity, Major Depressive Disorder, Chronic Obstructive Pulmonary Disease and more); eloralintide (Phase 3, Obesity, Osteoarthritis); mazdutide (Phase 3, Obesity, Type 2 Diabetes); retatrutide (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease and more)
Hansoh Pharmaceutical Group36923olatorepatide (Phase 3, Obesity, Type 2 Diabetes, Hidradenitis Suppurativa); Pegloxenatide (Fulaimei) (Phase 3, Type 2 Diabetes); Pegmolesatide (HS-20039) (Phase 3, Chronic Kidney Disease)
AstraZenecaAZN2Eneboparatide (Phase 3, Hypoparathyroidism); Lenbelintide (Phase 3, Obesity)
Gan & Lee Pharmaceuticals6030872Bofanglutide (Phase 3, Obesity, Type 2 Diabetes); GZR33 (Phase 3, Type 2 Diabetes)
Hangzhou Zhongmei Huadong Pharmaceutical0009632HDG1901 (Phase 3, Type 2 Diabetes); HDM1005 (Phase 3, Obesity, Type 2 Diabetes)
PfizerPFE2Berobenatide (Phase 3, Obesity, Type 2 Diabetes); ecnoglutide (Phase 3, Obesity, Type 2 Diabetes, Osteoarthritis)
RocheRHHBY2enicepatide (Phase 3, Obesity, Type 2 Diabetes); petrelintide (Phase 3, Obesity)
Zealand PharmaZEAL2petrelintide (Phase 3, Obesity); survodutide (Phase 3, Obesity, Type 2 Diabetes, MASH / NASH)
A. Menarini—1Bofanglutide (Phase 3, Obesity, Type 2 Diabetes)
AdociaADOC1THDB0206 (Phase 3, Type 2 Diabetes)
AltimmuneALT1pemvidutide (Phase 3, MASH / NASH)
AmgenAMGN1maridebart cafraglutide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more)
Amylyx Pharmaceuticals, Inc.AMLX1avexitide (Phase 3, Post-Bariatric Hypoglycemia)
Beijing QL Biopharmaceutical—1zovaglutide (Phase 3, Obesity)
BioMarin PharmaceuticalBMRN1BMN 333 (Phase 2/3, Achondroplasia)
Boehringer Ingelheim—1survodutide (Phase 3, Obesity, Type 2 Diabetes, MASH / NASH)
BrightGene Bio-Medical Technology6881661BGM0504 (Phase 3, Obesity, Type 2 Diabetes)
China Resources Sanjiu Medical & Pharmaceutical0009991BGM0504 (Phase 3, Obesity, Type 2 Diabetes)
Chugai Pharma45191enicepatide (Phase 3, Obesity, Type 2 Diabetes)
ConjuChem—1Albenatide (Phase 3, Type 2 Diabetes)
Everest Medicines (Beijing) Co., Ltd.19521MT1013 (Phase 3, Chronic Kidney Disease, Secondary Hyperparathyroidism)
Frontier Biotechnologies6882211Albuvirtide (Phase 3, HIV)
GemVax & KAEL0822701Tertomotide (Phase 3, Alzheimer's Disease, Pancreatic Cancer)
Guangdong Raynovent Biotech—1RAY1225 (Phase 3, Obesity, Type 2 Diabetes)
Haisco Pharmaceutical Group0026531Anrikefon (HSK21542) (Phase 3, Chronic Kidney Disease)
Hanmi Pharmaceutical1289401efpeglenatide (Phase 3, Obesity, Type 2 Diabetes)
Hebei Changshan Biochemical Pharmaceutical Co., Ltd3002551Albenatide (Phase 3, Type 2 Diabetes)
Innovent Biologics18011mazdutide (Phase 3, Obesity, Type 2 Diabetes)
Ironwood PharmaceuticalsIRWD1apraglutide (Phase 3, Short Bowel Syndrome)
JW Pharmaceutical0010601Bofanglutide (Phase 3, Obesity, Type 2 Diabetes)
Kailera TherapeuticsKLRA1ribupatide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more)
Laboratorios Sanfer—1efpeglenatide (Phase 3, Obesity, Type 2 Diabetes)
Lifeward Ltd.LFWD1ORMD-0801 (Phase 3, Type 2 Diabetes, MASH / NASH)
Lupin LimitedLUPIN1Bofanglutide (Phase 3, Obesity, Type 2 Diabetes)
Merck & Co.MRK1Enlicitide (Phase 3, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia)
Palatin TechnologiesPTN1PL9643 (Phase 3, Dry Eye Disease)
PegBio25651Visepegenatide (PB-119) (Phase 3, Type 2 Diabetes)
Qilu Pharmaceutical—1RAY1225 (Phase 3, Obesity, Type 2 Diabetes)
Regeneron PharmaceuticalsREGN1olatorepatide (Phase 3, Obesity, Type 2 Diabetes, Hidradenitis Suppurativa)
Sciwind Biosciences—1ecnoglutide (Phase 3, Obesity, Type 2 Diabetes, Osteoarthritis)
Shaanxi Micot Pharmaceutical Technology23351MT1013 (Phase 3, Chronic Kidney Disease, Secondary Hyperparathyroidism)
Shanghai HEP Pharmaceutical—1hepalatide (Phase 3, Chronic Hepatitis B, Chronic Hepatitis Delta)
Tonghua Dongbao Pharmaceutical6008671THDB0206 (Phase 3, Type 2 Diabetes)
United Bio-Technology (Hengqin)—1UBT251 (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease)
Viking TherapeuticsVKTX1VK2735 (Phase 3, Obesity, Type 2 Diabetes)

Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.